Agilent Call Buyers Step In Ahead of August Earnings

Options traders are leaning bullish on Agilent Technologies as the stock builds toward its August 20 earnings date. Three distinct signals are now pointing in the same direction.

Why this matters: The put-call ratio has dropped to a two-month low of 0.52, against a 20-day mean of 0.59. The z-score of -1.40 confirms this isn't noise — call buying has picked up meaningfully. At the same time, short sellers have added positions sharply, and borrowing costs have climbed. That combination — bulls buying calls, bears adding shorts — suggests the market is positioning for a big earnings move. Agilent's last print on May 27 moved the stock 17.6% in a single day.

Calls Dominate Into Earnings

The PCR hit 0.50 on July 27 — the 52-week low — before settling at 0.52 by July 31. That compares to a 52-week high of 1.19. The trend is clear: the options market has shifted away from hedging and toward directional call exposure over the past two weeks. With earnings on August 20, the timing is not coincidental.

The mean analyst price target stands at $159.32. The stock closed at $138.37 on July 31. That implies roughly 15% upside to consensus. Evercore ISI raised its target to $148 in early July. Barclays and B of A Securities both lifted targets in June. The analyst community has been broadly constructive.

Shorts Build — But the Borrow Is Cheap

Short interest jumped 41.6% over one week to 7.54 million shares, or 2.67% of free float. That is a notable move in percentage terms. In absolute terms, it remains a low short position for a stock of this profile.

Cost to borrow rose 68% week-on-week to 0.46%. That sounds dramatic. The actual rate is still very cheap. Availability remains exceptionally high at 6,533% of estimated short interest — meaning roughly 65 shares are available to borrow for every one currently lent out. There is no supply constraint driving these shorts. This looks like fresh directional positioning, not a crowded squeeze candidate.

The short score sits at 33.8, up from 31 a week ago. The shift is modest but consistent with the increase in short shares.

What Analysts Say

The bull case centres on pharma reshoring tailwinds, growth in spectroscopy, and strong guidance for FY2026. The bear case points to China exposure and sensitivity to the macro cycle.

Six of the most recent analyst actions were positive — raises or reinstates with Outperform or Overweight ratings. Piper Sandler initiated at Neutral in June, the lone cautious voice. The consensus stands well above current market price.

BlackRock added 261,470 shares in the latest quarter. T. Rowe Price added 828,315. Pictet added nearly 1 million shares. Institutional flows are net positive.

Data Summary

• PCR: 0.52 vs 20-day mean of 0.59; z-score -1.40; 52-week low 0.497
• Short interest: 7.54M shares, 2.67% of free float; +41.6% in one week
• Cost to borrow: 0.46%; +68% week-on-week
• Availability: 6,533% of short interest — abundant supply
• Short score: 33.8 (up from ~31 one week ago)
• Analyst mean target: $159.32 vs last close $138.37
• Next earnings: August 20, 2026; last print moved stock +17.6% in one day